Hologic, Inc. $HOLX Shares Sold by Chevy Chase Trust Holdings LLC

Key Points

• Chevy Chase Trust Holdings LLC reduced its stake in Hologic, Inc. by 34.2% during the second quarter, selling 61,250 shares, leaving it with 117,705 shares valued at approximately $7.67 million.
• Several analysts have raised their price targets for Hologic, with UBS Group reporting a target increase from $65.00 to $70.00 and Royal Bank of Canada raising its target to $87.00.
• CEO Stephen P. Macmillan sold 138,358 shares of Hologic's stock for over $9.26 million, reducing his ownership stake by 10.08%.

Chevy Chase Trust Holdings LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 34.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 117,705 shares of the medical equipment provider's stock after selling 61,250 shares during the quarter. Chevy Chase Trust Holdings LLC owned 0.05% of Hologic worth $7,670,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Nordea Investment Management AB lifted its stake in shares of Hologic by 7.2% during the second quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider's stock worth $168,674,000 after purchasing an additional 174,828 shares in the last quarter. Praxis Investment Management Inc. lifted its stake in shares of Hologic by 145.0% during the second quarter. Praxis Investment Management Inc. now owns 9,530 shares of the medical equipment provider's stock worth $621,000 after purchasing an additional 5,640 shares in the last quarter. Bridges Investment Management Inc. lifted its stake in shares of Hologic by 15.6% during the second quarter. Bridges Investment Management Inc. now owns 26,847 shares of the medical equipment provider's stock worth $1,749,000 after purchasing an additional 3,620 shares in the last quarter. TD Asset Management Inc lifted its stake in shares of Hologic by 1.4% during the second quarter. TD Asset Management Inc now owns 1,530,317 shares of the medical equipment provider's stock worth $99,715,000 after purchasing an additional 21,005 shares in the last quarter. Finally, Morningstar Investment Management LLC acquired a new position in shares of Hologic during the second quarter worth about $357,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on HOLX shares. UBS Group boosted their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Morgan Stanley boosted their price target on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and boosted their price target for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Mizuho set a $75.00 price target on Hologic in a research note on Thursday, July 31st. Finally, Stephens reiterated an "overweight" rating and issued a $78.00 price target on shares of Hologic in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and an average price target of $80.15.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the company's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.88% of the stock is owned by insiders.

Hologic Trading Up 2.9%

Shares of NASDAQ HOLX opened at $71.87 on Tuesday. The stock's 50 day moving average price is $67.19 and its two-hundred day moving average price is $63.62. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The stock has a market capitalization of $15.99 billion, a P/E ratio of 29.82, a PEG ratio of 2.40 and a beta of 0.63. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the prior year, the firm posted $1.06 earnings per share. Hologic's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.